Apellis Pharmaceuticals Inc (APLS)
28.82
+0.08
(+0.28%)
USD |
NASDAQ |
Nov 08, 10:41
Apellis Pharmaceuticals Revenue (TTM): 715.22M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 715.22M |
| June 30, 2024 | 628.79M |
| March 31, 2024 | 524.07M |
| December 31, 2023 | 396.59M |
| September 30, 2023 | 272.88M |
| June 30, 2023 | 184.53M |
| Date | Value |
|---|---|
| March 31, 2023 | 105.89M |
| December 31, 2022 | 75.42M |
| September 30, 2022 | 113.05M |
| June 30, 2022 | 96.64M |
| March 31, 2022 | 80.94M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
75.42M
Minimum
Dec 2022
715.22M
Maximum
Sep 2024
290.37M
Average
184.53M
Median
Jun 2023
Revenue (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 2.753B |
| Ionis Pharmaceuticals Inc | 803.07M |
| EyePoint Pharmaceuticals Inc | 50.39M |
| Cassava Sciences Inc | -- |
| Macrogenics Inc | 139.77M |